Monthly Archives

August 2018

New TB Study Has Hopeful Results

By | disease, research

Tuberculosis (TB), an infectious disease targeting the lungs, is the second biggest killer, globally.  In 2015, 1.8 million people died from the disease, with 10.4 million falling ill, despite the development of vaccines and effective drug treatment.  At one point, the United Nations predicted that TB would be eliminated worldwide by 2025, but treatment options remain surprisingly sparse.  The only vaccine for TB was developed nearly a century ago, and offers limited protection.  Even worse,  patients are becoming increasingly resistant to available drugs.

Read More

Can an Asthma Drug Reverse Dementia?

By | Uncategorised

Dementia is a term describing a variety of diseases that develop when nerve cells in the brain die or become impaired. The death of neurons causes changes in memory, behavior, physical capabilities and personality. In many of these diseases, such as Alzheimers, the associated changes often prove to be fatal.

Read More

Louisiana Hepatitis C Cost Proposal

By | legal, legislation

      As drug costs continue to capture national attention and the Trump Administration tries its hand at providing relief, Louisiana has rolled out a proposal that the state believes can help assist with affording the high cost of hepatitis C drugs.  Hepatits C is a blood borne infectious disease caused by the Hepatitis C virus, with no cure or vaccine currently available.  Globally, an estimated 71 million people have chronic hepatitis C infection, and a significant number of those who are chronically infected will develop cirrhosis or liver cancer.

Read More

Researchers Generate Immune Cells to Create Cancer Vaccines

By | Uncategorised

Cancer is a leading cause of death worldwide, accounting for 8.8 million deaths in 2015.  Cancer arises from the transformation of normal cells into tumor cells in a multistage process that generally progresses from a pre-cancerous lesion to a malignant tumor.  With so many patients and families affected by cancer, research in this area is a constant source of interest.

Read More

Biosimilars: Growing Pains in a New Arena

By | Uncategorised

One of the key strategies for enhancing access to affordable medicines posed by the Trump administration involved establishing the pathway for the development and approval of high-quality biosimilar therapies.  Yet, out of 11 approved products, only three biosimilars are on the market eight years after the enactment of legislation streamlining the process.  If current trends continue, it may be months or years before Americans gain access to these medications.

Read More